Tower Research Capital (TRC)’s Freeline Therapeutics Holdings FRLN Stock Holding History
Bought
Maintained
Sold
Other funds holding FRLN
Tower Research Capital (TRC)'s FRLN Position: Q4 2021 in Review
Tower Research Capital (TRC) sold out of Freeline Therapeutics Holdings (FRLN) in Q4 2021, closing a stake of 13 shares — an estimated $1K sold.
Tower Research Capital (TRC) first reported a position in FRLN in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 18 funds tracked by Wall St. Rank hold FRLN as of Q4 2021.
- Tower Research Capital (TRC) reported no remaining Freeline Therapeutics Holdings position as of Q4 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 13 Freeline Therapeutics Holdings shares in Q4 2021, an estimated $1K.
- Tower Research Capital (TRC) first reported a position in Freeline Therapeutics Holdings in Q3 2021 and held it in 1 quarter.
- Tower Research Capital (TRC)'s Freeline Therapeutics Holdings position peaked at $1K in Q3 2021.
- 18 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q4 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2021, filed 14 Feb 2022.